SBI-115

Catalog No.S6806 Batch:S680601

Print

Technical Data

Formula

C14H13ClN2O4S
Molecular Weight 340.78 CAS No. 882366-16-7
Solubility (25°C)* In vitro DMSO 68 mg/mL (199.54 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
3.4mg/ml Taking the 1 mL working solution as an example, add 50 μL of 68 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
3.4mg/ml Taking the 1 mL working solution as an example, add 50 μL of 68 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SBI-115 is a novel TGR5 (GPCR19) antagonist. SBI-115 decreases cell proliferation, cholangiocyte spheroid growth and cAMP levels in cystic cholangiocytes.
Targets
TGR5 [1]
In vitro

SBI-115, an inhibitor of TGR5, abolishes UDCA induced inhibition on cell growth (HCT116 cells, SW480 cells).[1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    HCT116 cells, SW480 cells

  • Concentrations

    100μM

  • Incubation Time

    24 h

  • Method

    HCT116 and SW480 cells are pretreated with 100μM TGR5 antagonist SBI-115 for 24 h, and then treated with UDCA for 36 h. Cell proliferation is measured using MTT assays.

Selleck's SBI-115 has been cited by 3 publications

Conjugated Bile Acids Promote Lymphangiogenesis by Modulation of the Reactive Oxygen Species-p90RSK-Vascular Endothelial Growth Factor Receptor 3 Pathway [ Cells, 2023, 12(4)526] PubMed: 36831193
Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation [ Nat Commun, 2022, 13(1):3419] PubMed: 35701426
Ursodeoxycholic Acid Suppresses The Malignant Progression of Colorectal Cancer Through TGR5-YAP Axis [ Research Square, 2021, 10.21203/rs.3.rs-274411/v1] PubMed: N/A

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.